Mereo BioPharma
MREO
56 hedge funds and large institutions have $90.4M invested in Mereo BioPharma in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 15 reducing their positions, and 6 closing their positions.
3,479% more call options, than puts
Call options by funds: $680K | Put options by funds: $19K
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
7% more capital invested
Capital invested by funds: $84.3M → $90.4M (+$6.12M)
6% more funds holding
Funds holding: 53 → 56 (+3)
0.27% less ownership
Funds ownership: 10.32% → 10.06% (-0.27%)
13% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$12.8M |
| 2 |
CC
Clearline Capital
New York
|
+$1.54M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.06M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$841K |
| 5 |
6CM
683 Capital Management
New York
|
+$796K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$4.69M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$2.97M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$398K |
| 4 |
JP Morgan Chase
New York
|
-$227K |
| 5 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
-$202K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Wells Fargo
San Francisco,
California
| $296 | -$6.63K | -5,000 | -96% |
|
52
Barclays
London,
United Kingdom
| $98 | +$50 | +38 | +100% |
|
|
PMFA
53
Plante Moran Financial Advisors
Southfield,
Michigan
| $62 | – | – | – |
|
54
US Bancorp
Minneapolis,
Minnesota
| $17 | – | – | – |
|
55
BNP Paribas Financial Markets
Paris,
France
| $4 | – | – | – |
|
|
BBA
56
Baker Bros. Advisors
New York
| – | -$4.69M | -3,554,979 | Closed |
|
|
BC
57
Boxer Capital
San Diego,
California
| – | -$2.97M | -2,250,000 | Closed |
|
58
Envestnet Asset Management
Chicago,
Illinois
| – | -$98.6K | -74,727 | Closed |
|
|
NFSG
59
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$12.5K | -9,500 | Closed |
|
60
UBS Group
Zurich,
Switzerland
| – | -$3.29K | -2,491 | Closed |
|
|
HCM
61
Highlander Capital Management
Short Hills,
New Jersey
| – | +$169 | +127 | New |
|
MREO Hedge Fund Activity: Q3 2023 in Review
56 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q3 2023, worth a combined $90.4M — up 7.3% from $84.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MREO positions and 6 closed out — a net gain of 4 holders — while 13 added to existing stakes and 15 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $12.8M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.69M sold.
- 56 institutional investors held Mereo BioPharma (MREO) as of Q3 2023, up from 53 in Q2 2023.
- Funds reported $90.4M of Mereo BioPharma stock for Q3 2023, up 7.3% quarter-over-quarter.
- 10 funds opened new Mereo BioPharma positions in Q3 2023 and 6 closed out, a net change of +4 holders.
- The largest Mereo BioPharma buyer in Q3 2023 was Soleus Capital Management, an estimated $12.8M added.
- The largest Mereo BioPharma seller in Q3 2023 was Baker Bros. Advisors, an estimated $4.69M sold.
Based on aggregated 13F filings for Q3 2023.